Indaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor Conference
March 28, 2024 08:00 ET
|
Indaptus Therapeutics
NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection...
Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting
March 25, 2024 08:30 ET
|
Indaptus Therapeutics
Data demonstrates that Company’s Decoy platform successfully induces or activates multiple immune cell types involved in anti-tumor responses New data shows activity in M1 macrophages, natural...
Indaptus Therapeutics to Participate in Tribe Public Webinar On Wednesday, March 20, 2024
March 18, 2024 08:00 ET
|
Indaptus Therapeutics
“Fully Engaging The Human Immune System To Cure Disease,” Featuring CEO, Jeffrey MecklerRegistration now open at INDPMarch2024.TribePublic.com NEW YORK, March 18, 2024 (GLOBE NEWSWIRE) --...
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
March 13, 2024 07:30 ET
|
Indaptus Therapeutics
Announced Positive Results from Second Cohort of Phase 1 Trial of Decoy20 Initiating Multi-Dosing for patients with solid tumors NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics,...
Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort
March 04, 2024 07:30 ET
|
Indaptus Therapeutics
• Positive data following completion of second cohort of Phase 1 trial of Decoy 20 leads independent Safety Review Committee to recommend initiating multi-dosing cohort • Single dose cohort data...
Indaptus Therapeutics to Present at the 2024 BIO CEO & Investor Conference
February 15, 2024 08:00 ET
|
Indaptus Therapeutics
NEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection...
Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels
February 08, 2024 08:00 ET
|
Indaptus Therapeutics
NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection...
European Patent Office Approves Key Patent for Indaptus Therapeutics’ Platform Technology
January 04, 2024 08:00 ET
|
Indaptus Therapeutics
NEW YORK, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biopharma company that utilizes a proprietary killed, non-pathogenic bacteria-based platform...
Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 06, 2023 16:01 ET
|
Indaptus Therapeutics
NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced financial results for the third quarter ended September 30, 2023...
Indaptus Therapeutics’ Decoy20 Demonstrated a Broad Immune Response of More than Fifty Cytokines and Chemokines in Patients Following a Single Dose in First Cohort of Ongoing Phase 1 Study
November 06, 2023 08:00 ET
|
Indaptus Therapeutics
NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical biopharma company that utilizes a proprietary killed, non-pathogenic bacteria-based platform to...